Research programme: multiple sclerosis therapies - Alberta/Novartis
Latest Information Update: 09 Dec 2013
At a glance
- Originator Alberta Innovates - Health Solutions; Novartis Pharmaceuticals Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple sclerosis
Most Recent Events
- 27 Nov 2013 Early research in Multiple sclerosis in Canada (unspecified route)